Aquestive Therapeutics (AQST)
NASDAQ:AQST
US Market

Aquestive Therapeutics Stock Price & Analysis

1,583 Followers

AQST Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.62 - $6.25
Previous Close$0.91
Volume83.15K
Average Volume (3M)569.02K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$18.65M
Total Debt (Recent Filing)$55.09M
Price to Earnings (P/E)-0.6
Beta1.95
Next EarningsMar 16, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.63
Shares Outstanding54,156,014
R-Squared0.23
Standard Deviation0.33
10 Day Avg. Volume189,099
30 Day Avg. Volume569,018
Price to Book (P/B)-0.44
Price to Sales (P/S)1.02
Price to Cash Flow (P/CF)38.20
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside415.86% Upside
Rating ConsensusStrong Buy
Alpha-0.03
Number of Analyst Covering6


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

AQST FAQ

What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $0.62 and its highest was $6.25 in the past 12 months.
    What is Aquestive Therapeutics’s market cap?
    Currently, no data Available
    When is Aquestive Therapeutics’s upcoming earnings report date?
    Aquestive Therapeutics’s upcoming earnings report date is Mar 16, 2023 which is in 96 days.
      How were Aquestive Therapeutics’s earnings last quarter?
      Aquestive Therapeutics released its earnings results on Nov 01, 2022. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.059.
        Is Aquestive Therapeutics overvalued?
        According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aquestive Therapeutics pay dividends?
          Aquestive Therapeutics does not currently pay dividends.
          What is Aquestive Therapeutics’s EPS estimate?
          Aquestive Therapeutics’s EPS estimate is -$0.25.
            How many shares outstanding does Aquestive Therapeutics have?
            Aquestive Therapeutics has 54,156,013 shares outstanding.
              What happened to Aquestive Therapeutics’s price movement after its last earnings report?
              Aquestive Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went down -2.326%.
                Which hedge fund is a major shareholder of Aquestive Therapeutics?
                Among the largest hedge funds holding Aquestive Therapeutics’s share is Caxton Associates LP. It holds Aquestive Therapeutics’s shares valued at N/A.

                  ---

                  Aquestive Therapeutics Stock Smart Score

                  6
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  The Aquestive Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aquestive Therapeutics

                  Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Odonate Therapeutics
                  Cognition Therapeutics
                  TherapeuticsMD
                  Lipocine

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis